Ipratropium bromide intranasal - Chiesi
Alternative Names: RinoAtem; RinoAtem AquaLatest Information Update: 24 Oct 2021
At a glance
- Originator Chiesi
- Class Antiasthmatics; Antibronchitics; Atropine derivatives; Bronchodilators; Small molecules
- Mechanism of Action Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease; Rhinitis
Most Recent Events
- 08 Jun 2010 No development reported - Phase-III for Rhinitis in Italy (Intranasal)
- 08 Jun 2010 No development reported - Preregistration for Asthma in Italy (Intranasal)
- 08 Jun 2010 No development reported - Preregistration for Chronic obstructive pulmonary disease in Italy (Intranasal)